These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22012257)

  • 1. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
    Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
    Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
    Afsar NA; Haenisch S; Mateen A; Usman A; Ufer M; Ahmed KZ; Ahmad HR; Cascorbi I
    Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):570-6. PubMed ID: 20102361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
    Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
    Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
    Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
    Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
    Helsby N; Yong M; Burns K; Findlay M; Porter D
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
    Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
    J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
    Kalra S; Kaur RP; Ludhiadch A; Shafi G; Vashista R; Kumar R; Munshi A
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1291-1298. PubMed ID: 29938344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
    Sreerama L; Sládek NE
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
    Sweeney C; Ambrosone CB; Joseph L; Stone A; Hutchins LF; Kadlubar FF; Coles BF
    Int J Cancer; 2003 Mar; 103(6):810-4. PubMed ID: 12516103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
    Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
    Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
    Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
    Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.
    Busse D; Busch FW; Bohnenstengel F; Eichelbaum M; Fischer P; Opalinska J; Schumacher K; Schweizer E; Kroemer HK
    J Clin Oncol; 1997 May; 15(5):1885-96. PubMed ID: 9164199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
    Tulsyan S; Agarwal G; Lal P; Mittal B
    Clin Chim Acta; 2014 Jul; 434():21-8. PubMed ID: 24768782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.
    Timm R; Kaiser R; Lötsch J; Heider U; Sezer O; Weisz K; Montemurro M; Roots I; Cascorbi I
    Pharmacogenomics J; 2005; 5(6):365-73. PubMed ID: 16116487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
    Fernandes BJ; Silva Cde M; Andrade JM; Matthes Ado C; Coelho EB; Lanchote VL
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):897-904. PubMed ID: 21290248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
    Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
    Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a
    Ming Z; Yongqiang Z; Zijin Z; Yan X; Di C; Xiaoxin T
    Pharmacogenomics; 2019 Nov; 20(16):1119-1124. PubMed ID: 31686598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.